Safety and pharmacodynamic effects of a pharmacological chaperone on alpha-galactosidase A activity and globotriaosylceramide clearance in Fabry disease: report from two phase 2 clinical studies
Dominique P Germain, Roberto Giugliani, Derralynn A Hughes, Atul Mehta, Kathy Nicholls, Laura Barisoni, Charles J Jennette, Alexander Bragat, Jeff Castelli, Sheela Sitaraman, David J Lockhart, Pol F Boudes
Orphanet Journal of Rare Diseases | BMC | Published : 2012
DPG is an investigator for Amicus and has received research funding, consultancy fees, and travel expenses from Genzyme and Shire HGT. RG is a consultant and investigator for Actelion, Amicus, BioMarin, Genzyme and Shire HGT. DAH is a consultant for Amicus, Shire HGT, Genzyme, Actelion, has Speaker's Bureau for Amicus, Shire HGT, Genzyme, and Actelion, and has received grants from Amicus, Shire HGT, and Genzyme. KN has received travel and research support and speaker's honoraria from Amicus, Shire HGT and Genzyme. AM has received honoraria, research funding, consultancy fees, and travel expenses from Shire HGT, Genzyme, Actelion, Protalix, and Amicus. AB, JC, SS, DJL and PFB are Amicus employees.